My Companies
Notification
Account
Log Out
Login
Novartis India secured exclusive Indian promotion and distribution rights for NHPL’s retina products Accentrix and Pagenax, supporting entry into ophthalmology, for an upfront payment of ₹10 crore. Context: first entry into a new therapy area.
Evonile Pharma Board Approves ₹900 Crore Partly Paid Rights Issue
Evonile Pharma Board Approves ₹900 Crore Partly Paid Rights Issue
Novartis India Acquires Minipress Rights For ₹1,250 Crore
Novartis India Approves ₹1,250 Crore Minipress Acquisition From Pfizer
Novartis India Terminates Dr Reddy’s Exclusive Distribution Agreement